Clinical Trials · NCT07509112
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Kirby Institute
- Enrollment
- 40
- Start date
- Sep 2026
- Locations
- 5 sites, Australia
- Primary endpoint
- Efficacy Outcome (exploratory)